FRANKFURT (Reuters) – Germany’s federal drug regulator BfArM said on Wednesday it will take the lead in an investigation into counterfeit versions of Novo Nordisk’s Ozempic injection pens for diabetes that have been found in the country.
In a statement, BfArm urged drug wholesale distributors and pharmacies to be extra vigilant when selling Ozempic to be able to intercept any counterfeit versions that may circulate.
(Reporting by Ludwig Burger)
